帕博利珠单抗治疗引起的严重口腔糜烂性类扁平苔藓样反应。
Severe oral erosive lichenoid reaction to pembrolizumab therapy.
机构信息
Professor and Division Director, Oral & Maxillofacial Pathology, Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, USA.
Professor, Oral & Maxillofacial Pathology, Department of Oral Diagnosis, Creighton University School of Dentistry, Omaha, NE, USA.
出版信息
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Nov;130(5):e301-e307. doi: 10.1016/j.oooo.2020.06.014. Epub 2020 Jun 27.
New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.
癌症免疫疗法的新进展正在迅速涌现。程序性死亡蛋白 1 抑制剂派姆单抗（Keytruda）于 2014 年上市，已被用于治疗多种癌症。派姆单抗和其他免疫检查点抑制剂相关的免疫相关不良事件现在是众所周知的并发症。我们描述了一位 65 岁女性的病例，她在膀胱癌治疗中使用派姆单抗后出现严重的口腔苔藓样病变。据我们所知，这是首例通过直接免疫荧光证实的活检证实的口腔糜烂性苔藓样反应的报告。
Zotero 插件